Education
School ¡X Major ¡X Degree | Duration |
---|---|
°ê¥ß¤¤¤s¤j¾Ç ¡X ¥Íª«Âå¾Ç¬ã¨s©Ò(²¦) ¡X ³Õ¤h Doctorate, Institute of Biomedical Sciences, National Sun Yat-sen University |
2011/09 ¡X 2017/03 |
°ê¥ß»OÆW¤j¾Ç ¡X ¤fµÄ¥Íª«¬ì¾Ç¬ã¨s©Ò(²¦) ¡X ºÓ¤h Master, Graduate Institute of Oral Biology, National Taiwan University |
2009/09 ¡X 2011/06 |
°ª¶¯Âå¾Ç¤j¾Ç ¡X ¥Íª«Âå¾Çº[Àô¹Ò¥Íª«¾Ç¨t(²¦) ¡X ¾Ç¤h Bachelor, Department of Biomedical Science and Environment Biology, Kaohsiung Medical University |
2005/09 ¡X 2009/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
¬ã¨sµo®i³B¾Ç³N¬ã¨s²Õ Division of Academic Research | Head | 2024/08/01 ¡X 2025/07/31 |
¾Ç¤h«áÂå¾Ç¨t School of Post-Baccalaureate Medicine | Associate Professor | 2022/08/01 ¡X |
¾Ç¤h«áÂå¾Ç¨t School of Post-Baccalaureate Medicine | Assistant Professor | 2020/08/01 ¡X 2022/07/31 |
¹êÅç¶EÂ_¾Ç¬ì Department of Laboratory Medicine | Assistant Professor | 2018/02/01 ¡X 2020/07/31 |
Extramural Experience
Discipline
NO | Discipline | Expertise |
---|---|---|
1 | ¥Íª«Âå¹AÃþ Biology, Medicine and Agriculture | ¥Íª«¾Ç¤§¥Í¤Æ¤Î¤À¤l¥Íª« Biochemistry and Molecular Biology |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
°ò¦]ÀË´ú¡B§ÜÅéÃĪ«¶}µo¡B³J¥ÕÃĪ«¶}µo
Genetic diagnosis, Antibody drugs development, protein drugs development
Area(s) of Expertise & Research
§K¬Ì¾Ç¡B³J¥Õ½èÅé¾Ç¡B¤À¤l²ÓM¥Íª«¾Ç¡B¹êÅç¶EÂ_¾Ç³J¥Õ½èÃĪ«¶}µo¡B¤À¤l§K¬Ì¾Ç¡B§ÜÅé°ò¦]¤uµ{¡B¸~½F¥Íª«¾Ç¡BÁ{§ÉÀË´ú
Protein drugs development, Molecular immunology, Antibody engineering, Cancer biology, clinical diagnosis
Publication
NO | Publication |
---|---|
1 | Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication. |
2 | A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis A lesion selective albumin CTLA4Ig as a safe and effective treatment for collagen induced arthritis |
3 | A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis A Low-Cost, Sensitive Reporter System Using Membrane-Tethered Horseradish Peroxidase for Efficient Gene Expression Analysis |
4 | Inhibition of gut microbial £]-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. Inhibition of gut microbial £]-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. |
5 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group |
6 | Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study. |
7 | Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules Engineering a High-Affinity Anti-Methoxy Poly(ethylene glycol) (mPEG) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics and mPEG Molecules |
8 | Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe Micro-PET imaging of hepatitis C virus NS3/4A protease activity using a protease-activatable retention probe |
9 | Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. Structural determination of an antibody that specifically recognizes polyethylene glycol with a terminal methoxy group. |
10 | Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. |
11 | Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice |
12 | Selective activation of pro-anti-IL-1£] antibody enhances specificity for autoinflammatory disorder therapy. Selective activation of pro-anti-IL-1£] antibody enhances specificity for autoinflammatory disorder therapy. |
13 | Ab Locks for Improving the Selectivity and Safety of Antibody Drugs Ab Locks for Improving the Selectivity and Safety of Antibody Drugs |
14 | Bispecific antibody (HER2 ¡Ñ mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Bispecific antibody (HER2 ¡Ñ mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. |
15 | ¥H¤À¤l¼ÒÀÀ¶i¦æ Tsg101 UEV ³J¥Õ»PÀôª¬Ð`肽§í¨î¾¯¤§¬ã¨s Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations |
16 | Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer |
17 | Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein |
18 | »E¤A¤G¾JªºIgM©MIgG§ÜÅ駡¥i¥H§ïÅÜ¥Ò®ñ°ò»E¤A¤G¾J-ªíÆ[³J¥Õ£]¦b¤p¹«¤¤ªº¥Íª«¬¡©Ê Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice |
19 | Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy |
20 | «Øºc¥i³Q³J¥Õ酶¬¡¤Æªº¿ï¾Ü©Ê§ÜÅé Selective antibody activation through protease-activated proantibodies that mask binding sites with inhibitory domains |
21 | Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules |
22 | ¤W¥Ö²ÓMÖߪþ¤À¤l³z¹L¿E¬¡«½sµ{¦]¤l©Mµ²¸zÀù¤¤¤W¥Ö¶¡½èÂà¤Æ°ò¦]ªí¹F½Õ¸`¸~½F°_©l©M¸~½Fµo¥Í Epithelial Cell Adhesion Molecule Regulates Tumor Initiation and Tumorigenesis via Activating Reprogramming Factors and Epithelial-Mesenchymal Transition Gene Expression in Colon Cancer |
Project
NO |
YEAR ¡X Source ¡X No ¡X Type
Project Name
|
Duration |
---|---|---|
1 |
113 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC113-2314-B-037-042 ¡X 1 Ó¤H«¬
¶}µo¨ã³J¥Õ?¬¡¤Æ¯S©Ê¤§«eÅX§Üµ{§Ç²ÓM¦º¤`³J¥Õ¤@«¬§ÜÅé¥H´£¤É¨Ó¨º«×Ói»P¦a¶ë¦ÌªQ¦X¨ÖªvÀø¦hµo©Ê°©Åè½F¤§Àø®Ä»P¦w¥þ©Ê( )
|
2024/08/01 ~ 2025/07/31 |
2 |
112 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(A)113013 ¡X
±´°QÅÖºûì¼Ë³J¥Õ¥[³tÃþ·Àã©ÊÃö¸`ª¢¤p¹«¼Ò¦¡ªÍ³¡µoª¢¤§¾÷¨î»PªvÀøµ¦²¤( )
|
2024/01/01 ~ 2024/12/31 |
3 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2628-B-037-001 ¡X 1 Ó¤H«¬
¶}µo³J¥Õ酶¥i¿E¬¡¤§«eÅX§Üì´O¦X¨üÅéT²ÓM(Pro-CAR-T)¥H´£¤É§K¬Ì²ÓMÀøªk¹ï¯e¯f°Ï°ì¤§¿ï¾Ü©Ê¡B§ÜÀùÀø®Ä¨Ã°§C°Æ§@¥Î(3/3)( )
|
2023/08/01 ~ 2024/07/31 |
4 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2813-C-037-081-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
113¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¶À¸WêM(¥Íª«3)( )
|
2024/07/01 ~ 2025/02/28 |
5 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2813-C-037-082-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
113¦~«×¤j±M¾Ç¥Í¬ã¨spµe-·¨¶®´@(¥Íª«3)( )
|
2024/07/01 ~ 2025/02/28 |
6 |
111 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(B)112002-1 ¡X 2 ¾ã¦X«¬
¶}µo«eÅX§Ü ROR1 ´O¦X¨üÅé T ²ÓM¥HªvÀø¤T³±©Ê¨ÅÀù¨Ã°§C°Æ§@¥Î( )
|
2023/01/01 ~ 2023/12/31 |
7 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST111-2628-B-037-010 ¡X 1 Ó¤H«¬
¶}µo³J¥Õ酶¥i¿E¬¡¤§«eÅX§Üì´O¦X¨üÅéT²ÓM(Pro-CAR-T)¥H´£¤É§K¬Ì²ÓMÀøªk¹ï¯e¯f°Ï°ì¤§¿ï¾Ü©Ê¡B§ÜÀùÀø®Ä¨Ã°§C°Æ§@¥Î(2/3)( )
|
2022/08/01 ~ 2023/07/31 |
8 |
110 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(B)111004-1 ¡X
±´°Q§®§Q´²¯q¥Íµß»P £]-catenin §í¨î¾¯¥iÂà´«§K¬Ì¬¡©Ê§C¸~½F(cold tumor)¬°§K¬Ì¬¡©Ê °ª¸~½F(hot tumor)¤§¾÷¨î( )
|
2022/01/01 ~ 2022/12/31 |
9 |
110 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST110-2628-B-037-010 ¡X 1 Ó¤H«¬
¶}µo³J¥Õ酶¥i¿E¬¡¤§«eÅX§Üì´O¦X¨üÅéT²ÓM(Pro-CAR-T)¥H´£¤É§K¬Ì²ÓMÀøªk¹ï¯e¯f°Ï°ì¤§¿ï¾Ü©Ê¡B§ÜÀùÀø®Ä¨Ã°§C°Æ§@¥Î(1/3)( )
|
2021/08/01 ~ 2022/07/31 |
10 |
110 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X ¡X 2 ¾ã¦X«¬
¥Hªü¯÷®üÀq¯g¤p¹«°Êª«¼Ò¦¡±´°Q¹ï»ÄÆP«×¥i±±ªºÂù¥\¯à§ÜÅé©ó¬¡Å餺¤§ÃĪ«°Ê¤O¾Ç¡B¥Íª«¤À¥¬»PªvÀøÀø®Ä( )
|
2021/01/01 ~ 2021/12/31 |
11 |
110 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST111-2813-C-037-031-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
111¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¾GÄí(¥Íª«3)( )
|
2022/07/01 ~ 2023/02/28 |
12 |
109 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(B)110006-3 ¡X
«Ø¥ß°Ó«~¤Æanti-PEG§ÜÅéÀË´úELISA kit¨ÓÀË´ú¯f¤H¦å²M¤¤anti-PEG§ÜÅé§t¶q¥Î¥H³Ì¨Î¤ÆPEG×¹¢ÃĪ«(Lipo-Dox)¤§¨Ï¥Î( )
|
2021/01/01 ~ 2021/12/31 |
13 |
109 ¡X KC °ªÂ嶧©ú¥æ¤j ¡X NCTUKMU109-DR-02 ¡X 1 Ó¤H«¬
¥HHepG2²ÓM¼Ò¦¡±´°Q§Üµoª¢ÃĪ«ªvÀø¯×ªÕ¨x®t²§ªí²{°ò¦]( )
|
2020/08/01 ~ 2021/07/31 |
14 |
109 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST110-2813-C-037-037-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
110¦~«×¤j±M¾Ç¥Í¬ã¨spµe-§õ¨Î©É(¥Í§Þ3)( )
|
2021/07/01 ~ 2022/02/28 |
15 |
109 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST110-2813-C-037-038-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
110¦~«×¤j±M¾Ç¥Í¬ã¨spµe-½²¤¹ºd(¥Í§Þ3)( )
|
2021/07/01 ~ 2022/02/28 |
16 |
108 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(¾ã)109004~3 ¡X
PolyGlycero×¹¢ÃĪ«ªº§K¬Ì©Ê´ú¸Õ¤ÎÀË´ú¸Õ¾¯¶}µo( )
|
2020/01/01 ~ 2020/12/31 |
17 |
108 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST107-2320-B-037-028-MY2 ¡X 1 Ó¤H«¬
¶}µo¥i³Q³J¥Õ酶¤ô¸Ñ¤§ÄÀ±±Âù¥\¯à§ÜÅé¥H¬ï³z¦å¸£»Ù¾À¨Ã´£¤Éªü¯÷®üÀq¯gªvÀø®ÄªG(2/2)( )
|
2019/08/01 ~ 2020/07/31 |
18 |
108 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X NSYSUKMU108-I008-3 ¡X 2 ¾ã¦X«¬
利¥Î´¹Åéµ²ºc¸ÑªR°ª¿Ë©M力anti-PD-1 §ÜÅé-§Üì½Æ¦Xª«¤§¥¿½Tµ²¦X¦ì¥HÀu¤Æ¹q¸£¹w´ú¨t²Î¤§精½T©Ê( )
|
2019/01/01 ~ 2019/12/31 |
19 |
108 ¡X Q ·s¸u±Ð®vpµe(®Õ¤º) ¡X KMU-Q109002 ¡X
¶}µoPro-Canakinumab (Pro-anti-IL-1£] Ab)«eÅX§ÜÅéÃĪ«¿ï¾Ü©Ê¤¤©M¯f¨_°Ï¤§IL-1£]§Üì¥H´£¤ÉºC©Êªý¶ë©ÊªÍ¯fÀø®Ä¨Ã°§C°Æ§@¥Î( )
|
2020/01/01 ~ 2020/12/31 |
20 |
108 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST109-2813-C-037-043-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
109¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¤è«ïªÚ(¥Í§Þ3)( )
|
2020/07/01 ~ 2021/02/28 |
21 |
107 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST107-2320-B-037-028-MY2 ¡X 1 Ó¤H«¬
¶}µo¥i³Q³J¥Õ酶¤ô¸Ñ¤§ÄÀ±±Âù¥\¯à§ÜÅé¥H¬ï³z¦å¸£»Ù¾À¨Ã´£¤Éªü¯÷®üÀq¯gªvÀø®ÄªG(1/2)( )
|
2018/08/01 ~ 2020/07/31 |
22 |
107 ¡X Q ·s¸u±Ð®vpµe(®Õ¤º) ¡X KMU-Q108001 ¡X
§Q¥Î¸~½F®û¼íB²ÓM¶}µo·s¿o¤j¸zª½¸zÀù¯g¶EÂ_¤ÎªvÀø¼Ðªº¤§±M¤@©Ê§ÜÅéÃĪ«( )
|
2019/01/01 ~ 2019/12/31 |
23 |
107 ¡X Y °ªÂå-¹ü°ò¦X§@pµe ¡X 108-CCH-KMU-010 ¡X 1 Ó¤H«¬
Âù¥\¯à§ÜÅé(£\HER2„~£\-mPEG)¤@¨B»sµ{½á¤©¿}苷Âà´«·L¯×Åé(GSL)¸~½F±M¤@©Ê¡A¥H´£¤É¨ÅÀù¤Î§Z±_Àù¤§¼Ð¹vÀø®Ä( )
|
2019/01/01 ~ 2019/12/31 |
Patent
NO | Patent Name | Country | Certified Date | Patent No |
---|---|---|---|---|
1 | ¤G¯Å§ÜÅé©Ò¿ëÃѤ§§Üì¨M©w¦ì¤Î¨ä¥Î³~ | ¤¤µØ¥Á°ê | 2017/08/01 | I593967 |
2 | ¤G¯Å§ÜÅé©Ò¿ëÃѤ§§Üì¨M©w¦ì¤Î¨ä¥Î³~ | ¬ü°ê | 2016/10/04 | 9,458,243 |
3 | ¤G¯Å§ÜÅé©Ò¿ëÃѤ§§Üì¨M©w¦ì¤Î¨ä¥Î³~ | ¬ü°ê | 2019/01/15 | 10,180,433 |
4 | ±±¨î°A´C¶Ç¬V¯e¯f¶Ç¼½¤§·L¥Íª«»s¾¯ | ¤¤µØ¥Á°ê | 2021/05/21 | I728264 |